Joel Greenblatt Coherus Bio Sciences, Inc. Transaction History

Gotham Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $118,984 - $178,803	-10,896 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $15 - $18	1 Added 0.01%	10,896 $174,000
Q3 2021 Nov 15, 2021	SELL	$12.68 - $17.79 $9,205 - $12,915	-726 Reduced 6.25%	10,895 $175,000
Q2 2021 Aug 16, 2021	BUY	$12.95 - $15.41 $17,741 - $21,111	1,370 Added 13.36%	11,621 $161,000
Q1 2021 May 17, 2021	BUY	$14.42 - $21.39 $147,819 - $219,268	10,251 New	10,251 $150,000
Q4 2020 Feb 16, 2021	SELL	$16.56 - $18.94 $324,807 - $371,489	-19,614 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$17.41 - $19.89 $835,784 - $954,839	-48,006 Reduced 70.99%	19,614 $360,000
Q2 2020 Aug 13, 2020	SELL	$14.43 - $19.16 $993,866 - $1.32 Million	-68,875 Reduced 50.46%	67,620 $1.21 Million
Q1 2020 May 15, 2020	BUY	$11.67 - $22.53 $163,520 - $315,690	14,012 Added 11.44%	136,495 $2.21 Million
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $1.71 Million - $2.24 Million	104,968 Added 599.3%	122,483 $2.21 Million
Q3 2019 Nov 14, 2019	BUY	$16.3 - $23.37 $285,494 - $409,325	17,515 New	17,515 $355,000

132

76.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $91.7M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.